Open Access<p>Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database</p>
Author(s) -
Yasuhiro Matsumura
Publication year - 2020
Publication title -
drug, healthcare and patient safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 24
ISSN - 1179-1365
DOI - 10.2147/dhps.s257009
Subject(s) - eculizumab , medicine , meningococcal disease , population , mortality rate , adverse effect , pediatrics , disease , epidemiology , septic shock , adverse event reporting system , sepsis , intensive care medicine , neisseria meningitidis , immunology , environmental health , complement system , antibody , biology , bacteria , genetics
Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients on eculizumab and to evaluate the effectiveness of risk communication.